Lopinavir/ritonavir (English Wikipedia)

Analysis of information sources in references of the Wikipedia article "Lopinavir/ritonavir" in English language version.

refsWebsite

Global rank English rank

12nih.gov

4^th place

8web.archive.org

1^st place

5doi.org

2^nd place

3drugs.com

399^th place

333^rd place

1canada.ca

1,712^th place

1,063^rd place

1europa.eu

68^th place

117^th place

1handle.net

102^nd place

76^th place

1medscape.com

719^th place

636^th place

1physorg.com

6,156^th place

5,640^th place

1fda.gov

447^th place

338^th place

1theconversation.com

928^th place

651^st place

1msn.com

117^th place

145^th place

1reuters.com

49^th place

47^th place

1cptech.org

low place

1ft.com

210^th place

157^th place

1aides.org

low place

aides.org

"People Living with HIV: Let's change the rules imposed by the pharmaceutical industry!" (PDF). AIDES. 1 July 2007. Archived from the original (PDF) on 20 October 2007.

canada.ca

health-products.canada.ca

"Kaletra Product information". Health Canada. 19 March 2019. Retrieved 18 March 2020.

cptech.org

"Decree of Department of Disease Control, Ministry of Public Health, regarding exploitation of patent on drugs & medical supplies by the government on combination drug between lopinavir & ritonavir" (PDF). Archived from the original (PDF) on 17 July 2011.

doi.org

Zhang L, Zhang Y, Huang SM (19 October 2009). "Scientific and regulatory perspectives on metabolizing enzyme-transporter interplay and its role in drug interactions: challenges in predicting drug interactions". Molecular Pharmaceutics. 6 (6): 1766–1774. doi:10.1021/mp900132e. PMID 19839641.
Sham HL, Kempf DJ, Molla A, Marsh KC, Kumar GN, Chen CM, et al. (December 1998). "ABT-378, a highly potent inhibitor of the human immunodeficiency virus protease". Antimicrobial Agents and Chemotherapy. 42 (12): 3218–3224. doi:10.1128/AAC.42.12.3218. PMC 106025. PMID 9835517.
Pasipanodya B, Kuwengwa R, Prust ML, Stewart B, Chakanyuka C, Murimwa T, et al. (December 2018). "Assessing the adoption of lopinavir/ritonavir oral pellets for HIV-positive children in Zimbabwe". Journal of the International AIDS Society. 21 (12): e25214. doi:10.1002/jia2.25214. PMC 6293134. PMID 30549217.
McCreary EK, Pogue JM (April 2020). "Coronavirus Disease 2019 Treatment: A Review of Early and Emerging Options". Open Forum Infectious Diseases. 7 (4): ofaa105. doi:10.1093/ofid/ofaa105. PMC 7144823. PMID 32284951.
Cao B, Wang Y, Wen D, Liu W, Wang J, Fan G, et al. (May 2020). "A Trial of Lopinavir-Ritonavir in Adults Hospitalized with Severe Covid-19". The New England Journal of Medicine. 382 (19): 1787–1799. doi:10.1056/NEJMoa2001282. PMC 7121492. PMID 32187464. This randomized trial found that lopinavir–ritonavir treatment added to standard supportive care was not associated with clinical improvement or mortality in seriously ill patients with Covid-19 different from that associated with standard care alone.

drugs.com

"Lopinavir and Ritonavir". The American Society of Health-System Pharmacists. Archived from the original on 20 December 2016. Retrieved 28 November 2016.
"Kaletra (lopinavir/ritonavir): Label Change - Serious Health Problems in Premature Babies". Drugs.com. Archived from the original on 11 March 2011.
"Generic Kaletra Availability". Drugs.com. Retrieved 18 February 2020.

europa.eu

ema.europa.eu

"Kaletra EPAR". European Medicines Agency (EMA). 17 September 2018. Retrieved 18 February 2020.

fda.gov

accessdata.fda.gov

"Drug Approval Package: Kaletra (Lopinavir/Ritonavir) NDA #21-226 & 21-251". U.S. Food and Drug Administration (FDA). 20 November 2001. Retrieved 18 March 2020.

ft.com

'Abbott pulls HIV drug in Thai patents protest', Financial Times (14 March 2007)

handle.net

hdl.handle.net

World Health Organization (2023). The selection and use of essential medicines 2023: web annex A: World Health Organization model list of essential medicines: 23rd list (2023). Geneva: World Health Organization. hdl:10665/371090. WHO/MHP/HPS/EML/2023.02.

medscape.com

"FDA Issues Safety Labeling Changes for Kaletra". Medscape. 10 April 2009. Archived from the original on 10 September 2017. Retrieved 18 March 2020.

msn.com

"Inoculating the world may mean reviving old curbs on patents". Pittsburgh Post-Gazette. Bloomberg. 14 April 2020. Retrieved 16 April 2020.

nih.gov

pubmed.ncbi.nlm.nih.gov

Zhang L, Zhang Y, Huang SM (19 October 2009). "Scientific and regulatory perspectives on metabolizing enzyme-transporter interplay and its role in drug interactions: challenges in predicting drug interactions". Molecular Pharmaceutics. 6 (6): 1766–1774. doi:10.1021/mp900132e. PMID 19839641.
Sham HL, Kempf DJ, Molla A, Marsh KC, Kumar GN, Chen CM, et al. (December 1998). "ABT-378, a highly potent inhibitor of the human immunodeficiency virus protease". Antimicrobial Agents and Chemotherapy. 42 (12): 3218–3224. doi:10.1128/AAC.42.12.3218. PMC 106025. PMID 9835517.
Pasipanodya B, Kuwengwa R, Prust ML, Stewart B, Chakanyuka C, Murimwa T, et al. (December 2018). "Assessing the adoption of lopinavir/ritonavir oral pellets for HIV-positive children in Zimbabwe". Journal of the International AIDS Society. 21 (12): e25214. doi:10.1002/jia2.25214. PMC 6293134. PMID 30549217.
McCreary EK, Pogue JM (April 2020). "Coronavirus Disease 2019 Treatment: A Review of Early and Emerging Options". Open Forum Infectious Diseases. 7 (4): ofaa105. doi:10.1093/ofid/ofaa105. PMC 7144823. PMID 32284951.
Cao B, Wang Y, Wen D, Liu W, Wang J, Fan G, et al. (May 2020). "A Trial of Lopinavir-Ritonavir in Adults Hospitalized with Severe Covid-19". The New England Journal of Medicine. 382 (19): 1787–1799. doi:10.1056/NEJMoa2001282. PMC 7121492. PMID 32187464. This randomized trial found that lopinavir–ritonavir treatment added to standard supportive care was not associated with clinical improvement or mortality in seriously ill patients with Covid-19 different from that associated with standard care alone.

ncbi.nlm.nih.gov

Sham HL, Kempf DJ, Molla A, Marsh KC, Kumar GN, Chen CM, et al. (December 1998). "ABT-378, a highly potent inhibitor of the human immunodeficiency virus protease". Antimicrobial Agents and Chemotherapy. 42 (12): 3218–3224. doi:10.1128/AAC.42.12.3218. PMC 106025. PMID 9835517.
Pasipanodya B, Kuwengwa R, Prust ML, Stewart B, Chakanyuka C, Murimwa T, et al. (December 2018). "Assessing the adoption of lopinavir/ritonavir oral pellets for HIV-positive children in Zimbabwe". Journal of the International AIDS Society. 21 (12): e25214. doi:10.1002/jia2.25214. PMC 6293134. PMID 30549217.
McCreary EK, Pogue JM (April 2020). "Coronavirus Disease 2019 Treatment: A Review of Early and Emerging Options". Open Forum Infectious Diseases. 7 (4): ofaa105. doi:10.1093/ofid/ofaa105. PMC 7144823. PMID 32284951.
Cao B, Wang Y, Wen D, Liu W, Wang J, Fan G, et al. (May 2020). "A Trial of Lopinavir-Ritonavir in Adults Hospitalized with Severe Covid-19". The New England Journal of Medicine. 382 (19): 1787–1799. doi:10.1056/NEJMoa2001282. PMC 7121492. PMID 32187464. This randomized trial found that lopinavir–ritonavir treatment added to standard supportive care was not associated with clinical improvement or mortality in seriously ill patients with Covid-19 different from that associated with standard care alone.

aidsinfo.nih.gov

"Adult and Adolescent Guidelines". AIDSinfo. 4 May 2006. Archived from the original on 6 May 2006. Retrieved 6 May 2006.
"What to Start: Initial Combination Regimens for the Antiretroviral-Naive Patient". AIDSinfo. 18 December 2019. p. Table 10. Antiretroviral Components or Regimens Not Recommended as Initial Therapy. Archived from the original on 31 August 2020. Retrieved 26 August 2020.

dailymed.nlm.nih.gov

"Kaletra- lopinavir and ritonavir tablet, film coated Kaletra- lopinavir and ritonavir solution". DailyMed. 26 December 2019. Retrieved 18 March 2020.

physorg.com

Foster C. "Research at Argonne helps Abbott Labs develop anti-HIV drug". Archived from the original on 22 October 2006. Retrieved 4 September 2006.

reuters.com

Scheer S (19 March 2020). "Israel approves generic HIV drug to treat COVID-19 despite doubts". Reuters. Retrieved 16 April 2020.

theconversation.com

Bonadio E, Baldini A (1 April 2020). "Drug companies should drop their patents and collaborate to fight coronavirus". The Conversation.

web.archive.org

"Lopinavir and Ritonavir". The American Society of Health-System Pharmacists. Archived from the original on 20 December 2016. Retrieved 28 November 2016.
"Adult and Adolescent Guidelines". AIDSinfo. 4 May 2006. Archived from the original on 6 May 2006. Retrieved 6 May 2006.
"What to Start: Initial Combination Regimens for the Antiretroviral-Naive Patient". AIDSinfo. 18 December 2019. p. Table 10. Antiretroviral Components or Regimens Not Recommended as Initial Therapy. Archived from the original on 31 August 2020. Retrieved 26 August 2020.
"FDA Issues Safety Labeling Changes for Kaletra". Medscape. 10 April 2009. Archived from the original on 10 September 2017. Retrieved 18 March 2020.
"Kaletra (lopinavir/ritonavir): Label Change - Serious Health Problems in Premature Babies". Drugs.com. Archived from the original on 11 March 2011.
Foster C. "Research at Argonne helps Abbott Labs develop anti-HIV drug". Archived from the original on 22 October 2006. Retrieved 4 September 2006.
"Decree of Department of Disease Control, Ministry of Public Health, regarding exploitation of patent on drugs & medical supplies by the government on combination drug between lopinavir & ritonavir" (PDF). Archived from the original (PDF) on 17 July 2011.
"People Living with HIV: Let's change the rules imposed by the pharmaceutical industry!" (PDF). AIDES. 1 July 2007. Archived from the original (PDF) on 20 October 2007.